Korean J Bone Metab > Volume 16(2); 2009 > Article
Korean Journal of Bone Metabolism 2009;16(2):65-69.
RANK Signaling-based New Drug Targets for Osteoporosis
RANK 신호전달계에 근거한 골다공증 치료제 타겟
최한경,김경희,신지혜,장현덕,이수영12
이화여자대학교 생명약학부, 이화여자대학교 생명과학과1, 이화여자대학교 바이오융합과학과2
Abstract
Increased osteoclastic bone resorption causes the loss in bone density observed in human diseases such as osteoporosis and arthritis. The discovery of the RANKL/RANK axis as the final effector of bone destruction has generated great expectations regarding the potential of some antagonists for the treatment of patients with various metabolic and inflammatory bone disorders. The signaling cascades initiated by RANKL uncover several new classes of antiresorptive therapeutic targets. Unraveling the entire RANK signaling networks will be beneficial for the development of new generations of therapeutics with higher efficacy and fewer side effects. [Korean Journal of Bone Metabolism, 16(2): 65-69, 2009]
Key Words: RANKL, RANK, Osteoclast, Bone resorption, Osteoporosis
TOOLS
METRICS Graph View
  • 1,024 View
  • 13 Download
Related articles

Diabetes and Osteoporosis2008 November;15(2)



ABOUT
ARTICLE CATEGORY

Browse all articles >

BROWSE ARTICLES
EDITORIAL POLICY
FOR CONTRIBUTORS
Editorial Office
#1001, Hyundai Kirim Officetel, 42 Seocho-daero 78-gil, Seocho-gu, Seoul 06626, Korea
Tel: +82-2-3473-2231    Fax: +82-70-4156-2230    E-mail: editors.jbm@gmail.com                

Copyright © 2024 by The Korean Society for Bone and Mineral Research.

Developed in M2PI

Close layer
prev next